Published: January 2020
Rise in prevalence of chronic diseases and the corresponding need to medicate frequently, have led to an increase in demand for safe, self-administrable dosing options. Autoinjectors are considered among the leading product classes in this category
Roots Analysis has announced the addition of “Global Autoinjectors Market (3rd Edition), 2020-2030” report to its list of offerings.
In addition to enabling patients to self-medicate, these devices are designed to ensure safety during the dosing process and promote compliance to prescribed therapeutic regimens. Moreover, the adoption of autoinjectors, and other self-injection products, has enabled significant cost savings for end users by eliminating the need to visit hospitals / out-patient clinics for dosing.
To order this 600+ page report, which features 360+ figures and 350+ tables, please visit this link
Close to 80 autoinjector devices are presently available / under development
About 80% of these devices are disposable and intended for single use only, while the others are designed to be reusable. Further, it is interesting to note that more than 40% of such devices have provisions that allow variable dose administration.
Nearly 120 autoinjector combination products are either already available or under investigation
Of these, ~90 autoinjectors are approved for use in the treatment of indications, such as rheumatoid arthritis and / or psoriasis (including other forms of arthritis), multiple sclerosis, anaphylaxis and organophosphate poisoning.
Till date, 4,600+ patents have been filed related to autoinjectors
Based on the intellectual property distribution across the world, R&D activity is currently concentrated in the US, Australia and China. Most patented inventions were observed to be focused on the development of innovative trigger mechanisms and electronic feedback systems for drug delivery.
Over 120 drugs were identified as likely candidate to be made available in combination with autoinjectors
The report features insights on the likelihood of over 250+ marketed drugs and pipeline candidates, being developed in combination with autoinjectors. The analysis takes into consideration several parameters, such as current phase of development of the drug candidate, target indication, dosing frequency, type of drug molecule, annual sales (for marketed drugs) and available delivery systems (for marketed drugs).
The market is anticipated to grow at a CAGR of over 5%, during the period 2020-2030
Growth in this domain is anticipated to be primarily driven by the need to reduce healthcare costs and therapy administration in the homecare setting. North America (primarily the US) and Europe are expected to capture about 70% of the market share by 2030, in terms of the sales-based revenues.
To request a sample copy / brochure of this report, please visit this link
The USD 1.5 billion (by 2030) financial opportunity within the autoinjector devices market has been analyzed across the following segments:
The report features inputs from eminent industry stakeholders, according to whom autoinjectors address several limitations of conventional parenteral drug delivery process, by preventing accidental needle-stick injuries, dosing errors and are preferred even by patients with trypanophobia. The report includes detailed transcripts of discussions held with the following experts:
The research includes detailed company profiles, featuring an overview of the company, its financial information (if available), information on its product portfolio, autoinjector device specifications, collaborations, recent development and an informed opinion on the likely strategies that may be adopted by these players to fuel growth in the foreseen future.
For additional details, please visit
or email email@example.com
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry